Overview

PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis

Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-dose study to evaluate the PK profile of the liquid SC formulation of BIO89-100 in approximately 8 male and female subjects with NASH with compensated cirrhosis.
Phase:
Phase 1
Details
Lead Sponsor:
89bio, Inc.